<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00472056</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0271</org_study_id>
    <nct_id>NCT00472056</nct_id>
  </id_info>
  <brief_title>Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies</brief_title>
  <official_title>Randomized Trial Using Standard Dose Versus High Dose Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Diffuse Large B Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cohort 1: Patients who are less than or equal to 65 years of age.

      1. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose
      rituximab)

      Cohort 2: Patients who are older than 65 years of age

        1. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high
           dose rituximab)

        2. To determine the treatment related mortality (TRM)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carmustine, cytarabine, etoposide, melphalan, and rituximab are all standard chemotherapy
      drugs.

      If you are found to be eligible to take part in this study, you will be randomly assigned (as
      in the toss of a coin) to one of two treatment groups. Participants in one group will receive
      high dose rituximab with transplantation and high dose chemotherapy. Participants in the
      other group will receive standard dose rituximab with transplantation and high dose
      chemotherapy. The first 10 patients enrolled on this study will have an equal chance of being
      assigned to either group. After the first 10 participants are enrolled, the remaining
      participants will have a higher chance of being assigned to the group that has proven to be
      more effective.

      All participants will have a plastic tube (catheter) inserted under their collarbone. This
      catheter will be left in place for the entire treatment period. The catheter will be used to
      deliver most of the drugs and for the collection and transfusion of the stem cells. When
      possible, all drugs that need to be given by vein will be given using the catheter.

      Stem cell collection is done on a separate study and patients will take part in this study
      only after the stem cell collection is complete. You should have an adequate number of stem
      cells collected and stored before you can be eligible for high-dose chemotherapy and
      transplantation.

      All treatment will be given at M. D. Anderson. You will be admitted to the hospital to
      receive high dose chemotherapy and will stay in the hospital for 3-4 weeks. You will be given
      carmustine by vein over 1 hour on Day 1. On Days 2 - 5, you will be given cytarabine by vein
      over 1 hour and etoposide by vein over 3 hours. This will be repeated every 12 hours on Days
      2-5. On Day 6, you will be given melphalan by vein over 30 minutes. On Day 7, the stem cells
      that were collected earlier will be given back to you (&quot;transplanted&quot;) through the catheter
      over 30-45 minutes.

      You will also receive either high dose or standard dose rituximab by vein over 4-6 hours one
      day after the transplant (Day 1) and then again 1 week later (Day 8).

      You will receive G-CSF injections staring at Day 1 (one day after transplant or stem cell
      infusion). These will continue our cell count reaches the appropriate level for at least 3
      days in a row. Blood tests (2 teaspoons) will be done every day while you are in the hospital
      to track the effects of the transplant.

      You will be asked to return to M. D. Anderson at 3 months and 6 months after transplantation,
      then every 6 months for 3 years, and then once a year up to 5 years from the transplant date.
      At each visit you will get blood work (1-2 tablespoons), CT scans, and other tests like bone
      marrow (if needed) to determine the status of your lymphoma.

      This is an investigational study. All of the drugs used in this study are FDA approved and
      are commercially available. Up to 100 patients will take part in this study. All will be
      enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>Up to 5 years from transplant date.</time_frame>
    <description>DFS defined as time from transplantation to disease relapse, disease progression, death during remission, or last follow-up. Evaluation at 3 months and 6 months after transplantation, then every 6 months for 3 years, and then once a year up to 5 years from the transplant date.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>BEAM + Standard Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Rituximab with Standard Rituximab for Cohort 1 or 2
Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.
Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.
Standard Rituximab: 375 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEAM + High Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab
Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.
Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.
High Dose Rituximab: 1000 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>300 mg/m^2 IV for 1 Day</description>
    <arm_group_label>BEAM + Standard Rituximab</arm_group_label>
    <arm_group_label>BEAM + High Rituximab</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>BiCNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days</description>
    <arm_group_label>BEAM + Standard Rituximab</arm_group_label>
    <arm_group_label>BEAM + High Rituximab</arm_group_label>
    <other_name>VePesid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days</description>
    <arm_group_label>BEAM + Standard Rituximab</arm_group_label>
    <arm_group_label>BEAM + High Rituximab</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine arabinosine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>140 mg/m^2 IV x 1 Day</description>
    <arm_group_label>BEAM + Standard Rituximab</arm_group_label>
    <arm_group_label>BEAM + High Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Cohort 1, High-Dose Rituximab = 1000 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion.</description>
    <arm_group_label>BEAM + Standard Rituximab</arm_group_label>
    <arm_group_label>BEAM + High Rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically proven diffuse large B-cell (CD20 positive) or
             transformed follicular non-Hodgkin's lymphomas, that have relapsed after conventional
             chemotherapy and are not eligible for protocols of higher priority

          2. Patients must have chemosensitive disease to salvage chemotherapy and less than 5%
             bone marrow involvement with lymphoma by gross pathologic examination

          3. Age less than or equal to 80 years. There is no lower age limit for this study.

          4. Zubrod performance status of less than 2

          5. Negative pregnancy test in patients with child bearing potential

          6. Must be willing to sign informed consent

          7. Should be seronegative for HIV, hepatitis B surface antigen, hepatitis C antibody.

        Exclusion Criteria:

          1. Patients with known active CNS disease are excluded. Patients with prior history of
             CNS disease should have a negative MRI of the brain (and/or spine if indicated) and
             negative CSF cytology within 4 weeks of enrollment into the study.

          2. Less than 3 weeks from last cytotoxic chemotherapy

          3. Serum bilirubin &gt; 1.5 mg/dl

          4. Serum transaminases &gt; 2X/ULN

          5. Serum creatinine &gt; 1.6 mg/dl

          6. Failure to collect more than 3 x 1,000,000 CD34+ stem cells/kg body weight

          7. Left ventricular ejection fraction of &lt; 40%, unless cleared by cardiology

          8. Corrected DLCO of &lt; 50%

          9. Patients who are on anticoagulants or antiplatelet agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chitra M. Hosing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2007</study_first_submitted>
  <study_first_submitted_qc>May 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2007</study_first_posted>
  <results_first_submitted>January 9, 2012</results_first_submitted>
  <results_first_submitted_qc>January 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 13, 2012</results_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Lymphoid Malignancies</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>BEAM Chemotherapy</keyword>
  <keyword>Carmustine</keyword>
  <keyword>BCNU</keyword>
  <keyword>BiCNU</keyword>
  <keyword>Etoposide</keyword>
  <keyword>VePesid</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Cytosar</keyword>
  <keyword>DepoCyt</keyword>
  <keyword>Cytosine arabinosine hydrochloride</keyword>
  <keyword>Ara-C</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Rituxan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: March 03, 2005 to June 19, 2009. All recruitment done at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 65 Years of Age or Less With Arm 2</title>
          <description>Arm 2: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 Patients Who Are Older Than 65 Years of Age Arm 1</title>
          <description>Arm 1: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Dose Rituximab</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1 65 Years of Age or Less With Arm 1</title>
          <description>Arm 1: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Dose Rituximab</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2 Patients Who Are Older Than 65 Years of Age Arm 2</title>
          <description>Arm 2: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 65 Years of Age or Less With Arm 2</title>
          <description>Arm 2: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2 Patients Who Are Older Than 65 Years of Age Arm 1</title>
          <description>Arm 1: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Dose Rituximab</description>
        </group>
        <group group_id="B3">
          <title>Cohort 1 65 Years of Age or Less With Arm 1</title>
          <description>Arm 1: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Dose Rituximab</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2 Patients Who Are Older Than 65 Years of Age Arm 2</title>
          <description>Arm 2: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" spread="7.58288"/>
                    <measurement group_id="B2" value="70.2" spread="3.50522"/>
                    <measurement group_id="B3" value="53.3" spread="11.93155"/>
                    <measurement group_id="B4" value="69.8" spread="3.43211"/>
                    <measurement group_id="B5" value="61" spread="11.17466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival (DFS)</title>
        <description>DFS defined as time from transplantation to disease relapse, disease progression, death during remission, or last follow-up. Evaluation at 3 months and 6 months after transplantation, then every 6 months for 3 years, and then once a year up to 5 years from the transplant date.</description>
        <time_frame>Up to 5 years from transplant date.</time_frame>
        <population>Analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Rituximab</title>
            <description>Standard dose arm: Rituximab 375 mg/m^2 intravenous on days +1 and +8 after stem cell infusion.</description>
          </group>
          <group group_id="O2">
            <title>High Dose Rituximab</title>
            <description>High dose arm: Rituximab 1000mg/m^2 intravenous on days +1 and +8 after stem cell infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (DFS)</title>
          <description>DFS defined as time from transplantation to disease relapse, disease progression, death during remission, or last follow-up. Evaluation at 3 months and 6 months after transplantation, then every 6 months for 3 years, and then once a year up to 5 years from the transplant date.</description>
          <population>Analysis was per protocol.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.33" lower_limit="1.81" upper_limit="39.29"/>
                    <measurement group_id="O2" value="9.635" lower_limit="1.77" upper_limit="31.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 Years, 5 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 65 Years of Age or Less With Arm 2</title>
          <description>Arm 2: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2 Patients Who Are Older Than 65 Years of Age Arm 1</title>
          <description>Arm 1: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Dose Rituximab</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1 65 Years of Age or Less With Arm 1</title>
          <description>Arm 1: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Dose Rituximab</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2 Patients Who Are Older Than 65 Years of Age Arm 2</title>
          <description>Arm 2: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low Platelets</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to Thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="32"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="25"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="32"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="25"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="32"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chitra M. Hosing, MD / Associate Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>mvpacheco@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

